Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists
Por um escritor misterioso
Descrição
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists
Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)
Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts. - Abstract - Europe PMC
Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)
AS 6 陶术生物
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists
PDF) CXCR2 antagonism promotes oligodendrocyte precursor cell differentiation and enhances remyelination in a mouse model of multiple sclerosis
Sophie GONG, Sr. scientist, GlaxoSmithKline, London, GSK, R&D China
Directing the Metabolism of Drugs Away from CYP450: The Use of Oxetane Rings
AS 6 陶术生物
CXCR2 antagonism promotes oligodendrocyte precursor cell differentiation and enhances remyelination in a mouse model of multiple sclerosis - ScienceDirect
Advances in targeting Phosphodiesterase 1: From mechanisms to potential therapeutics - ScienceDirect
1-(3-tert-butylsulfonyl-4-cyano-2-hydroxyphenyl)-3 -[(1R)-2-methylcyclopent-2-en-1-yl]urea, C18H23N3O4S
CXCR2-IN-2, CXCR2 Antagonist
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists
de
por adulto (o preço varia de acordo com o tamanho do grupo)